Skip to main content
. Author manuscript; available in PMC: 2019 Dec 18.
Published in final edited form as: Biomater Sci. 2018 Dec 18;7(1):113–124. doi: 10.1039/c8bm01208c

Figure 5. Antibody- and VHH-mediated targeting of nanoparticles to T cells in vivo.

Figure 5.

(a) C57Bl/6 mice (n=3 animals/group) were injected i.v. with 150 µg amph-NPs or anti-CD8-NPs, and particle uptake in PBMCs was analyzed 24 hr later by mass cytometry. (b-d) C57Bl/6 mice (n=3 animals/group) were injected i.v. with 100 µg amph-NPs or VHH-NPs. Twenty-four hr later particle uptake in leukocytes was analyzed by mass cytometry. Shown is uptake in peripheral blood lymphocytes (b) and myeloid cells (c), representative mass cytometry plots from several cell populations showing percentages of NP+ cells (d), and quantitation of the mean NP+ cells (e). **** p < 0.0001; ***, p < 0.001; **, p < 0.01; *, p < 0.05; n.s. not significant by two-way ANOVA with Tukey’s multiple comparison test.